NL – Celltrion v. Hoffmann-La Roche et al.

Posted: October 5th, 2017

Celltrion Inc, v. F. Hoffmann-La Roche AG, Biogen Inc. and Genentech Inc., District Court of the Hague, 27 September 2017, Case No. ECLI:NL:RBDHA:2017:11301

Patent revoked due to lack of novelty. Priority can not be invoked since the priority right was not validly transferred.

A copy of the decision can be read here.

One Response

  1. Attentive observer says:

    Here is another case in which the priority was not valid due to a late transfer of this right.
    As a consequence a document published in the priority interval has be come lethal. what a way to loose a patent!
    The present case is similar to T 1201/14 and T 577/11.

Leave a Reply